ArticleFrontiers in aging2026
SARC-T a new physical test for sarcopenia assessment with development, validation and physiological evaluation.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia is a disease characterized by the progressive loss of muscle mass and strength associated with aging. There are marked differences in sarcopenia prevalence depending on the diagnostic algorithm used. It has been demonstrated that muscle power is the most relevant predictor for determining functional limitations in older adults. The objectives of this study were to evaluate the performance of the Sarcopenia Optoelectronic Chair-Rise Velocity Test (SARC-T) as complementary alternative to tests that determinate probable sarcopenia and/or assess its severity, as well as to assessment analyze its correlation with other validated tests. Methods: A cross-sectional analysis was conducted in a population residing in elderly care centers. All physical tests included in the second version of the diagnostic algorithm developed by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) in 2019 were performed. In addition, the SARC-T was administered to measure the speed at which participants rose from a chair. Physiological variables, including heart rate (HR), systolic blood pressure (SBP), and oxygen saturation (SpO Results: The sarcopenia group showed significantly lower physical performance than the non-sarcopenia group in all tests. At a physiological level, no significant differences were found between groups in the 5-STST, Handgrip, and TUG. Additionally, the SARC-T showed a strong correlation with Handgrip (r = 0.800), 5-STST (r = -0.719) and TUG (r = -0.523), and a moderate correlation with Gait Speed (r = -0.438) in sarcopenia group. Conclusion: The SARC-T could be a safe, accurate, and low-impact complementary tool for assessing the probability and severity of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.